Prevalence of risk phenotypes associated with CYP2C9*2, *3, and VKORC1 c.-1639G>A genetic polymorphisms in world populations: implications in clinical practice
To enhance the safety of at least 11 clinically significant drugs, the current study found that approximately one-fifth of the global population is at risk based on the <i>CYP2C9*2</i> and <i>*3</i> genotypes. Additionally, approximately one-third of the population is at risk when considering the combination of <i>CYP2C9</i> and <i>VKORC1 c.-1639G>A</i> genotypes. Further studies are warranted to evaluate the clinical benefits of integrating PGx-based therapies in routine practice.
Authors
- Most. Sumaiya Khatun Kali (ORCID: https://orcid.org/0000-0002-3363-0303)
- Mohitosh Biswas (ORCID: https://orcid.org/0000-0003-1432-7701)
- Chonlaphat Sukasem (ORCID: https://orcid.org/0000-0003-0033-5321)
- Maliheh Ershadian
- Baharudin Ibrahim (ORCID: https://orcid.org/0000-0001-8534-2517)
- Murshadul Alam Murad (ORCID: https://orcid.org/0009-0006-6113-0687)
- Maw Shin Sim (ORCID: https://orcid.org/0000-0002-7848-0775)
Institutions
- Burapha University (TH)
- Daffodil International University (BD)
- Mahidol University (TH)
- Bumrungrad International Hospital (TH)
- University of Malaya (MY)
- Ramathibodi Hospital (TH)
- University of Rajshahi (BD)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-09-19
- DOI
- https://doi.org/10.3389/fphar.2025.1597379
- Citations
- 2
- Primary Topic
- Pharmacogenetics and Drug Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 3.11